UNSPSC 51372116: Codeine sulfate

This classification denotes an opiate with the molecular formula 2C18H21NO3.3H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11QV9BS0CB, chemically known as morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-, sulfate (2:1) (salt) but more generally known as codeine sulfate, which bears US NIH Compound Identifier 5359613. European Medicines Agency schedules Codeine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01410MIG.

UNSPSC 51372116 Codeine sulfate (Commodity) names a specific pharmaceutical ingredient, but recent state and local procurement activity under this code spans broader pharmacy benefit management, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical procurement rather than codeine sulfate alone. State and local health departments, cooperative purchasing alliances, and county health authorities are the primary issuing bodies, with activity centered on securing pharmaceutical supply agreements, naloxone procurement for community health initiatives, and generic medication sourcing through authorized wholesalers. The work includes establishing vendor relationships for direct manufacturer contracts, negotiating net pricing and rebate structures, managing pharmacy benefit program logistics, and sourcing FDA-compliant generic pharmaceuticals with specific National Drug Codes and packaging configurations.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission released RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on vendors' experience with direct contracting for self-insured employers and outcomes-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon through authorized wholesalers, with pricing evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance, EDI capability, and pricing format options.